HF Advisory Group LLC Acquires 3,643 Shares of CVS Health Co. (NYSE:CVS)

HF Advisory Group LLC grew its holdings in CVS Health Co. (NYSE:CVS) by 35.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,926 shares of the pharmacy operator’s stock after acquiring an additional 3,643 shares during the quarter. HF Advisory Group LLC’s holdings in CVS Health were worth $1,100,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of CVS. Moneta Group Investment Advisors LLC increased its holdings in shares of CVS Health by 103,371.0% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,547,559 shares of the pharmacy operator’s stock worth $1,448,877,000 after acquiring an additional 15,532,533 shares in the last quarter. Norges Bank bought a new stake in shares of CVS Health in the fourth quarter worth about $1,425,416,000. FMR LLC boosted its position in shares of CVS Health by 29.1% during the third quarter. FMR LLC now owns 27,487,238 shares of the pharmacy operator’s stock worth $1,919,159,000 after buying an additional 6,194,441 shares during the period. Morgan Stanley boosted its position in shares of CVS Health by 10.9% during the fourth quarter. Morgan Stanley now owns 33,576,388 shares of the pharmacy operator’s stock worth $3,128,984,000 after buying an additional 3,311,928 shares during the period. Finally, Barclays PLC boosted its position in shares of CVS Health by 97.8% during the second quarter. Barclays PLC now owns 5,483,154 shares of the pharmacy operator’s stock worth $379,052,000 after buying an additional 2,711,102 shares during the period. 80.66% of the stock is currently owned by institutional investors.

Insider Transactions at CVS Health

In other news, EVP Prem S. Shah sold 29,473 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the transaction, the executive vice president now owns 39,765 shares in the company, valued at $3,059,916.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.24% of the stock is owned by corporate insiders.

CVS Health Stock Performance

Shares of CVS traded up $0.43 during mid-day trading on Thursday, reaching $69.03. The company’s stock had a trading volume of 1,495,656 shares, compared to its average volume of 10,776,160. CVS Health Co. has a 1-year low of $64.41 and a 1-year high of $83.25. The stock has a market cap of $87.01 billion, a P/E ratio of 10.71, a PEG ratio of 0.91 and a beta of 0.52. The business has a 50-day simple moving average of $75.53 and a two-hundred day simple moving average of $73.73. The company has a current ratio of 0.86, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. The company had revenue of $93.81 billion during the quarter, compared to analysts’ expectations of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The business’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm posted $1.99 earnings per share. As a group, equities research analysts anticipate that CVS Health Co. will post 8.32 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be paid a dividend of $0.665 per share. The ex-dividend date is Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.85%. CVS Health’s dividend payout ratio (DPR) is currently 41.18%.

Analyst Upgrades and Downgrades

CVS has been the subject of several recent research reports. HSBC initiated coverage on CVS Health in a research report on Friday, December 22nd. They set a “buy” rating and a $94.00 price objective for the company. Barclays assumed coverage on CVS Health in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $78.00 price objective for the company. Wells Fargo & Company reduced their price target on CVS Health from $83.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $87.00 price target on shares of CVS Health in a research report on Wednesday, April 10th. Finally, Piper Sandler increased their price target on CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $89.44.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.